Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.

The user reports progress in hair regrowth using finasteride every other day, topical minoxidil once daily, ketoconazole twice a week, and Vitamin D3 with zinc. They note improvement in temple areas and the appearance of baby hairs.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The conversation is about choosing the right concentration of tretinoin cream to enhance the absorption of minoxidil for hair loss treatment. The options discussed are 0.5, 0.05, 0.25, and 1mg/g concentrations.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The user has been inconsistently using a 0.1% finasteride and 5% minoxidil topical treatment for hair loss over the past nine months, along with 1% Nizoral once a week. They aim to improve consistency in their treatment this year and report no side effects.

User shared progress on crown regrowth using Minoxidil Foam, oral Minoxidil 2.5mg daily, and Finasteride 1mg daily. They experienced initial headaches with oral Minoxidil, had a hair transplant, and are seeing regrowth but with thin hairs.

After one year of using 1mg oral finasteride and 5% minoxidil daily, along with initial weekly microneedling that later became biweekly, the individual's hair appears improved. They have stopped microneedling but continue with finasteride and minoxidil.

People are using lower doses of finasteride than the recommended 1mg daily due to concerns about side effects, cost, and new data suggesting lower doses can be nearly as effective. Some users report stability or slight improvements with lower doses, but the effectiveness compared to 1mg daily is debated.

A 21-year-old male is starting treatment for hair loss with 1mg Finasteride daily and 5% Minoxidil foam twice a day, along with other hair care products and supplements. He plans to document his progress monthly and is concerned about potential side effects from Finasteride.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.

The conversation discusses using a 1.0mm dermaroller for hair loss, with the user experiencing mild redness that subsided quickly. The user seeks advice on the frequency of dermaroller use.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

A user received a prescription for Dutasteride 0.5 in Europe and asked about the brand. Replies confirmed the brand's quality and suggested using the cheapest gelatin capsule form.

User experienced hair growth after 1.5 months using Fin, 1 month using Min, and microneedling. They use liquid Rogaine twice daily, microneedle with a .4 mm dermaroller, and take oral Fin once a day.

The user saw no hair loss improvement for a year using 1mg finasteride and 5% minoxidil. They experienced better results after reducing finasteride to 0.25mg, adding a derma pen treatment, and applying a solution with minoxidil and melatonin.

The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.

Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.

Winlevi (clascoterone), a DHT blocker, is being considered for hair loss treatment, though it's primarily an acne medication. Users discuss its potential effectiveness and note it may only work for a short time.

A user reported significant facial aging after using minoxidil for hair loss, despite a good skincare routine and healthy lifestyle. They plan to switch to dutasteride and possibly stop minoxidil.

The user has been using 1mg finasteride and 2.5mg oral minoxidil daily for 18 months without success in treating hair loss. They are frustrated with their diffuse androgenetic alopecia and unsure of what to do next.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user has been taking 0.5 finasteride for 10 months and wants to repeat blood tests, including estradiol. However, their doctor is reluctant to test estradiol, arguing it's typically low in men, and the user is considering seeking a second opinion.

The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.